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Introduction
In the past year there has been an escalation of the age-old
crystalloid–colloid debate as a result of the publication of
several systematic reviews assessing the effect of various
colloids versus various crystalloids on mortality. In 1998, an
excess mortality of 4% for the colloid resuscitated patients
was claimed for various colloids versus various crystalloids
in various clinical scenarios [1]. A further systematic
review, published in July 1998 from the same lead author,
compared mortality in patients receiving human albumin
solutions with those who did not and concluded there was
a 6% excess mortality in the albumin group [2]. In 1999, a
systematic review claimed no difference in mortality for
colloid or crystalloid resuscitation where various colloids
were compared to various crystalloids in various hypo-
volaemic insults [3]. This commentary seeks to analyse the
systematic reviews critically and relate their findings to
clinical practice in the modern intensive care unit.
Data presented in the systematic reviews
Crystalloid versus colloid in fluid resuscitation [1]
A total of 26 trials were selected comparing a variety of
colloids carried in a variety of crystalloid solvents and
compared to a variety of crystalloids, including 3.5% gela-
tine in the crystalloid group in one study [4]. Of these
studies, mortality data were presented for 19 including
1315 patients. There was a claimed excess mortality of 4%
in colloid group [95% confidence interval (CI) 0–8%] with
a relative risk of 1.19 (95% CI 0.98–1.45).
Table 1 shows there was a bias towards inclusion of papers
using albumin or dextran as the colloid. This is not sur-
prising as these are the older colloids for which most com-
parative data exist. It is apparent that the only trials
contributing to the mortality effect of colloid used
albumin or dextran. The two dextran papers were by the
same authors [5,6] and both used hypertonic saline as the
crystalloid in trauma resuscitation. It is not clear whether
the colloid effect would be the same given with hyper-
tonic crystalloid as the effect when given with isotonic
crystalloid. In practice, there is an early, marked plasma
volume expansion with hypertonic crystalloid which is not
seen with isotonic crystalloid. This effect is short lived but
may be maintained if colloid is used in addition. Further-
more, the current accepted view for fluid resuscitation in
trauma is to secure haemostasis before full restoration of
circulating volume since full early restoration promotes
more bleeding. This is quite different to the management
of other (non-haemorrhaging) critically ill patients where
early restoration of circulating volume is considered to be
an urgent goal.
The albumin papers included one using 5% (not 50% as
stated in the review) albumin in acute respiratory distress
syndrome (ARDS) [7] and one using a low concentration
of albumin in burns patients [8]. In the series of Metildi et
al [7] there was an imbalance of illness severity between
the groups with an excess of septicaemic patients in the
crystalloid group, the difference in illness severity
accounting for the outcome differences. In the paper by
Goodwin et al [8] albumin apparently contributed heavily
to an excess mortality in the colloid group. Many burn
centres contend that crystalloid resuscitation is as effec-
tive as albumin resuscitation, although argument persists
over the role of larger molecular weight hydroxyethyl
starches. In many burn centres, fluid resuscitation is
guided by formulae rather than any physiological mea-
surement. General intensive care units treating burned
patients often discard the formula and resuscitate as they
would for any hypovolaemic patient, guided by filling
pressures and/or cardiac output measurements. Burned
patients endure massive capillary leak for several days and
it is easy to see why smaller molecular weight colloids
(including albumin) may not be useful. It is more difficult
to understand why a low concentration of albumin should
contribute anything, particularly death.
Albumin versus no albumin [2]
The second systematic review of 30 trials with mortality
data included 1419 patients with various concentrations of
albumin, various hypovolaemic insults and hypoalbu-
minaemia included as an indication. There was a claimed
excess mortality overall of 6% in albumin group (95% CI
CI = confidence interval; ARDS = acute respiratory distress syndrome; TPN = total parenteral nutrition.3–9%) with a relative risk for hypovolaemia of 1.46 (95%
CI 0.97–2.22) and for hypoalbuminaemia of 1.69 (95% CI
1.07–2.67).
It is worth noting that most of the studies using albumin
supplementation in hypoalbuminaemia used parenteral
nutrition fluids to which albumin had been added.
Although visual compatibility has been established for the
addition of albumin to total parenteral nutrition (TPN)
there is an increased risk of bacterial and fungal contamina-
tion of the solution and concentrations >2.5% may increase
particulate infusion [9]. Since albumin supplementation for
hypoalbuminaemia is rare in modern critical care practice
the systematic review supports current practice.
The search for papers using the indication of hypo-
volaemia produced 16 papers compared to seven using
albumin in the first systematic review [1]. The paper by
Metildi et al [7] was excluded from the second review
(perhaps on the basis that the authors did not realise that
ARDS patients receive fluid for hypovolaemia). The two
papers from the first review using mixed colloids were
included [10,11], but the data pertaining to albumin use
only extracted. In two papers [12,13] included in both sys-
tematic reviews a proportion of the patients were
excluded from one systematic review converting, in one
case [12], a relative risk favouring colloid to a relative risk
favouring control. It is of note that a further paper [8] was
included in the second review that was not included in the
first review. This raises questions on the search strategy.
If we consider the hypovolaemic patients in the albumin
review, half the papers suggested benefit and half sug-
gested an increased mortality. Of the seven papers sug-
gesting an increased mortality with albumin, three had
only one or two deaths in total [6,14,15] and two probably
represented a different patient group from the others (one
studying pre-term infants [16] and the other with a higher
overall mortality [17]). It is also noteworthy that Zetter-
strom’s work contributed to both an excess albumin
mortality [14] and an excess non-albumin mortality [18] in
the systematic review but these two papers were pub-
lished back to back and were two parts of a single on-
going investigation. It is not particularly convincing that
albumin kills if used in hypovolaemia.
The paper with the largest excess albumin mortality in the
second review was the paper by Lucas et al [19]. This was
a trauma study in which albumin was added to a standard-
ised fluid resuscitation regimen in the protocol group.
Thus patients were resuscitated to physiological goals
with blood, fresh plasma and balanced electrolyte solu-
tions in both treatment and control groups. There was no
reduction of crystalloid solution in the protocol group to
make space for the supplemental albumin. Patients died
predominantly of cardiopulmonary failure, a recognised
effect of excessive fluid resuscitation. It is by no means
clear that the albumin supplementation contributed to the
deaths, other than by the fluid excess mechanism. A com-
mentary printed immediately following the paper made
the point that the large volumes of blood and fresh frozen
plasma, given in equivalent quantities to both groups,
would have amounted to over 300g albumin; the 25–75g
supplement to the protocol group could not be expected
to have any additional pharmacological effect.
Crystalloid versus colloid in fluid resuscitation [3]
In a systematic review of 17 trials with mortality data,
including 814 patients, Choi et al [3] included various col-
loids and various crystalloids but no hypertonics. There were
various hypovolaemic insults. Papers were included accord-
ing to several methodological factors rather than simple allo-
cation concealment as used in the previous two reviews.
Although there was an imbalance of mortality favouring
crystalloids, the authors correctly made a claim of no excess
mortality, based on the statistical analysis. The different
selection process used in this review meant that five papers
were included that appeared in neither of the previous
reviews. However, there were 16 papers included in the pre-
vious reviews that were not included in this review.
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Table 1
Colloids assessed in the 1998 systematic review
Papers Patients Colloid Crystalloid
Papers contributing
Colloid nnn deaths n deaths to excess mortality
Albumin 7 381 180 29 201 23 3 of 7
Gelatin 1 22 11 0 11 0 0 of 1
Hydroxyethyl starch 1 41 21 2 20 2 0 of 1
Dextran 7 652 351 96 301 56 2 of 7
Plasma 1 153 74 30 79 30 0 of 1
Mixed 2 66 48 11 28 7 0 of 2Critique of trial selection
The role of other factors in mortality
The confounding factors of imbalance of illness severity,
different approaches to correction of physiological abnor-
malities and the interaction between other treatments that
are not controlled are not declared in a systematic review.
What the papers show is that some doctors can kill
patients with colloids. The way a drug is used is as impor-
tant a determinant of its effect as the properties of the
drug itself. Of course, the skilled user will be taking these
properties into account when judging how to use it.
The primary goal in the management of hypovolaemia is
to stop volume loss (if possible) and restore the circulating
volume. Many intensive care units use a fluid challenge
regimen [20]. A small increment of blood volume is
achieved (usually 200ml) and the effect of this is judged
by measurement of central venous pressure and/or cardiac
stroke volume. Other vital signs are usually taken into
account as well. This is repeated until there is no further
improvement with the blood volume increment. This way
the right amount of fluid is individualised to the patient
and fluid overload is rare. A fluid challenge requires the
use of colloid since a 200-ml increment of blood volume is
achieved with 200ml colloid versus at least 800ml isotonic
saline. Unfortunately we do not know, in the individual,
exactly how much of the saline will remain in the circula-
tion for long enough to make the physiological measure-
ments so no response may mean we have not given
enough or transvascular leak is greater. With colloids,
small molecules will leak but not at a rate that interferes
with the interpretation of the measurements. Other treat-
ment factors are almost certainly the reason for opposing
results in some trials included in the reviews.
The use of mortality as the outcome measure
Most of the papers reviewed have been designed to assess
their effects in terms of one or more physiological vari-
ables. They have been designed to assess mortality. A ran-
domised controlled trial comparing one colloid with one
crystalloid would require over 6500 patients to detect an
excess colloid mortality of 4% on the basis of the data in
the first systematic review. This assumes confounding
factors are evenly distributed between groups, a type I
error of 5% and a type II error of 2.5% with a control mor-
tality of 20%. I have argued above that the choice of agent
becomes less important if the way it is used is not well
controlled (in the clinical rather than statistical sense).
Unless we compare trials that have used the same end-
points in their design, the same physiological protocols for
fluid administration, the same protocols for other circula-
tory treatment (inotropes, vasopressors, vasodilators), the
same protocols for respiratory management and studied
patients with the same severity of illness throughout their
stay I cannot see how we can make a meaningful state-
ment on comparative mortality. Since most of these
studies are not designed to assess mortality as an outcome
these factors will not be controlled (in the statistical
sense).
The problem of biochemical rather than haemodynamic
endpoints
The albumin review demonstrated an excess mortality in
all studies using albumin for the indication of hypoalbu-
minaemia. The problem is that correction of a biochemical
endpoint as a primary goal in patients who do not other-
wise need the fluid runs the risk of the effects of fluid
excess. The easiest way of increasing colloid osmotic pres-
sure is to give large doses of diuretics. The easiest way of
reducing colloid osmotic pressure is to give large volumes
of crystalloids. Both techniques will substantially alter
blood volume. The currently accepted view is that main-
tenance of colloid osmotic pressure is of secondary impor-
tance to maintenance of circulating volume. It is true that
use of well retained colloids may prevent further reduc-
tions in colloid osmotic pressure but very few intensive
care units bother to measure colloid osmotic pressure. The
primary goal in clinical reality is to restore circulating
volume. Mortality from studies using fluid titrated to a
biochemical endpoint is not related to clinical reality.
Inappropriate grouping of study treatments
I criticised the first review because a variety of colloids
were considered as a single entity. I must make the same
criticism of the albumin review that included a variety of
albumin concentrations. It is important to understand that
different concentrations of solution [21], the different
molecular sizes and differences in electrical charge [22]
and degrees of substitution and effects of substituting dif-
ferent carbon atoms in the hydroxyethyl starch molecules
[23] all affect the physical and pharmacological properties
of these colloids. Failing to separate the individual prod-
ucts is like looking at the effects of different antibiotics
and grouping them according to chemical class rather than
microbial sensitivity patterns. No one would consider that
flucloxacillin is the same as benzylpenicillin, although
both are undoubtedly penicillins.
Conclusions
Concluding anything from these systematic reviews is dif-
ficult. As is usual from such reviews, a question is posed as
an input and a question is the output. Should we abandon
the use of colloid solutions in intensive care? The evi-
dence does not support such a conclusion; it simply
demonstrates colloids may not be a major determinant of
mortality. Since mortality was not the primary outcome
measure in any of the studies assessed, even this conclu-
sion has to be softened. Those of us who will continue to
use colloid solutions must ask ourselves why. On our list
of advantages we would never have cited a reduction in
mortality. The reality is that our choice of fluid for resusci-
tation is one small part of a package of measures that we
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A switch to exclusive crystalloid use for the experienced
colloid user would require a complete reassessment of
goals of therapy, changes in attitude to the tolerance of
oedema and its corresponding problems, changes in
trigger points for escalation to other circulatory and respi-
ratory support treatments and a re-education process that
is bound to be associated with errors (and deaths?) during
the phase of gaining experience in the methods.
Should we abandon the use of human albumin solutions?
The reality is that many had, long before the publication
of the systematic reviews, since there were cheaper alter-
natives available that are as and probably more effective.
Are we any the wiser? I have suggested the questions
posed by the reviews, as well as the answers, were invalid.
In that case we must agree that we are none the wiser.
However, focussing on the problems of interpretation of
the reviews leads us to understand a little more about the
importance of the process of intensive care, ie the inter-
play between many different treatments and the role of
those involved in delivering intensive care. Single treat-
ments have so often failed the test of the randomised con-
trolled trial in intensive care and this is not surprising in a
field where the whole is considerably greater than the sum
of its parts.
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